Skip to main content
OpenTrials
Completed

NCT Number: NCT00817999

The Impact of Grapefruit Juice on the Response to Clopidogrel

This study will measure the percentage of platelet aggregation inhibition with a loading dose of clopidogrel (300 mg) using the VerifyNow Assay System in healthy volunteers who have drank 11 oz of grapefruit juice. It will also measure the percentage of platelet aggregation inhibition with a maintenance dose of clopidogrel (75 mg/day) using the VerifyNow Assay System in healthy volunteers who have drank 11 oz grapefruit juice daily.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Age range

19 year–40 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

Creighton Cardiac Center

Omaha, Nebraska, 68131, United States

About this study

This study will examine the effect of GFJ on the loading dose (300 mg) of clopidogrel and will evaluate the effect of GFJ on the maintenance dose (75 mg/day) of clopidogrel. Subjects will be randomized to either initially receive GFJ prior to their loading dose of clopidogrel or receive GFJ prior to their second loading dose. The subjects who have been randomized to receive GFJ initially will drink two small cans (11 oz total) of regular strength GFJ in the morning, followed two hours later by a loading dose (300 mg) of clopidogrel and will then return to the clinic 6 hours after their loading dose to have their platelet inhibition measured. Subjects will have ~ 5 milliliters (1 teaspoonful) of whole blood drawn from an antecubital vein in their forearm via a 21 gauge needle attached to a blue-top plastic vacuette sodium citrate blood collection (Greiner, Monroe, NC) tube to test inhibition of platelet aggregation. After their first loading dose, a 2 week washout period will follow to allow for their platelet aggregation to return to normal. Following the washout period, the subjects will take their second loading dose of clopidogrel and again return to the clinic for platelet inhibition measurement. The same timing will be followed for the loading dose taken without prior GFJ.

During the maintenance dose phase of this study, subjects will take 75 mg/day clopidogrel for 7 days with or without GFJ. Subjects will be randomized to either GFJ during the first period or GFJ during the second period. A minimum 2 week washout period will occur between the two 7 day courses of clopidogrel. Platelet inhibition measurement will occur at the end of each 7 day period as described above.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Ages 19-40
  • Health status confirmed by medical history and physical examination and laboratory analysis

Exclusion criteria

  • Pregnancy
  • Taking routine prescription or over-the-counter prescriptions
  • Taken over-the-counter analgesic/anti-inflammatory medication within two weeks of study participation
  • Recently had grapefruit juice or regularly drinks grapefruit juice

Treatment and study plan

Grapefruit Juice

Dietary Supplement

Participants received grapefruit juice during 1 of the 2 periods.

Clopidogrel 75 mg/day

Drug

Clopidogrel 300 mg

Drug

Primary outcomes

  1. % Platelet Inhibition

    Time frame: 6 hours

    % platelet inhibition measured by Verify Now

Sponsors and collaborators

Lead sponsor

Creighton University

Other

Registry information

Official study title

The Impact of Grapefruit Juice on the Response to a Loading Dose and Maintenance Dose of Clopidogrel in Healthy Volunteers

Important dates

Study start
2008
Primary completion
2011
Study completion
2011
First posted
Jan 7, 2009
Registry last updated
Oct 1, 2012

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.